Literature DB >> 18852220

Diabetes mellitus complicating systemic lupus erythematosus - analysis of the UCL lupus cohort and review of the literature.

S Cortes1, S Chambers, A Jerónimo, D Isenberg.   

Abstract

Systemic lupus erythematosus (SLE) often coexists with other diseases. Diabetes mellitus (DM) is an example and patients with overlap SLE-DM can present with clinical features common to both disorders. In this review, we describe the patients with overlap SLE-DM, focussing on the clinical features common to both diseases that these patients can present, and on the challenges of managing such complications. A detailed review of the patients' notes (n = 485) was performed. At every outpatient appointment the patients' urine was tested for glucose, protein and blood. Patients with persistent glycosuria were investigated with fasting blood glucose and a glucose tolerance test to help make the diagnosis of DM. Particular note was made of those patients whose symptoms could be due to SLE, DM or both. Nine patients with DM were identified. Three had type 1 DM, four had type 2 DM and two were considered to have steroid-induced DM. Among these patients, three had renal involvement (two with WHO class IV lupus nephritis); two had peripheral neuropathy (one had a mixed sensory and motor neuropathy, one had a sensory peripheral neuropathy); two patients had retinopathy and cataracts and one had angina. The combination of SLE and DM is uncommon but the predisposition to renal, peripheral neuropathy and retinal disease means that great care must be taken when deciding which clinical feature is due to which disease, because active SLE requires additional immunosuppression whereas DM requires optimization of the metabolic control. Interestingly, although in theory patients with SLE and DM are in double-jeopardy of developing atherosclerosis, to date, only one of our overlap patients has developed angina.

Entities:  

Mesh:

Year:  2008        PMID: 18852220     DOI: 10.1177/0961203308091539

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  11 in total

1.  Manifestations of systemic lupus erythematosus.

Authors:  Manole Cojocaru; Inimioara Mihaela Cojocaru; Isabela Silosi; Camelia Doina Vrabie
Journal:  Maedica (Buchar)       Date:  2011-10

2.  Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Sara Kaprove Penn; Amy H Kao; Laura L Schott; Jennifer R Elliott; Frederico G S Toledo; Lewis Kuller; Susan Manzi; Mary Chester M Wasko
Journal:  J Rheumatol       Date:  2010-05-01       Impact factor: 4.666

3.  Association of systemic lupus erythematosus with angiographically defined coronary artery disease: a retrospective cohort study.

Authors:  Mala S Kaul; Sunil V Rao; Linda K Shaw; Emily Honeycutt; Stacy P Ardoin; E William St Clair
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-02       Impact factor: 4.794

Review 4.  Atherosclerosis in systemic lupus erythematosus.

Authors:  George Stojan; Michelle Petri
Journal:  J Cardiovasc Pharmacol       Date:  2013-09       Impact factor: 3.105

5.  Myocardial ischemia in Wegener's granulomatosis: coronary atherosclerosis versus vasculitis.

Authors:  Giuseppe Cocco; Armen Yuri Gasparyan
Journal:  Open Cardiovasc Med J       Date:  2010-02-23

6.  Nephropathy in Pparg-null mice highlights PPARγ systemic activities in metabolism and in the immune system.

Authors:  Barbara Toffoli; Federica Gilardi; Carine Winkler; Magnus Soderberg; Laura Kowalczuk; Yvan Arsenijevic; Krister Bamberg; Olivier Bonny; Béatrice Desvergne
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

Review 7.  Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus.

Authors:  Alberto Floris; Matteo Piga; Arduino Aleksander Mangoni; Alessandra Bortoluzzi; Gian Luca Erre; Alberto Cauli
Journal:  Mediators Inflamm       Date:  2018-02-18       Impact factor: 4.711

Review 8.  Cardiovascular risk in pediatric-onset rheumatological diseases.

Authors:  Julie Barsalou; Timothy J Bradley; Earl D Silverman
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

9.  Transcriptomic analysis of insulin-sensitive tissues from anti-diabetic drug treated ZDF rats, a T2DM animal model.

Authors:  Yo Na Kim; Sangok Kim; Il-Yong Kim; Jae Hoon Shin; Sooyoung Cho; Sun Shin Yi; Wan Kyu Kim; Kyung-Sub Kim; Sanghyuk Lee; Je Kyung Seong
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

10.  Recipient Glycemic Micro-environments Govern Therapeutic Effects of Mesenchymal Stem Cell Infusion on Osteopenia.

Authors:  Bing-Dong Sui; Cheng-Hu Hu; Chen-Xi Zheng; Yi Shuai; Xiao-Ning He; Ping-Ping Gao; Pan Zhao; Meng Li; Xin-Yi Zhang; Tao He; Kun Xuan; Yan Jin
Journal:  Theranostics       Date:  2017-03-06       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.